This review focused on efficacy and safety of biologic drugs used to treat inflammatory diseases in people with HIV.  Authors screened literature (inclusive to June 29, 2022) and included 112 studies involving 179 patients (> 80% were on ART).  12 studies described outcomes among 21 patients receiving dupilumab (IL-4 inhibitor), used primarily for atopic dermatitis: 57% experienced complete and 43% partial response.  33% experienced adverse events.  18 case reports/series described rituximab (CD20 inhibitor) among 25 patients, used mostly for kidney or hemolytic disease: response was mixed.  Adverse events occurred in 16%.  4 cases involving IL-5 and IGE inhibitors (mepolizumab and omalizumab, used for asthma and DRESS, and bullous pemphigoid and chronic spontaneous urticaria, respectively) were examined.  All 4 patients were successfully treated with no adverse events.  9 cases involved IL-17 inhibitors (brodalumab, ixekizumab, secukinumab) used for psoriasis and axial spondylarthritis: all had partial or complete response.  2 cases of secukinumab-associated adverse events were observed: candida esophagitis with erosive gastritis, and genital candidiasis—both responded to fluconazole.  Cases involving IL-23 inhibitors (guselkumab, risankizumab, ustekinumab) used primarily for psoriasis among 23 people indicated complete response for 4 and partial improvement for all others, without adverse events.  62 studies of TNF-alpha inhibitors (adalimumab, ethanercept, infliximab) involving 109 patients were included.  Psoriasis was the main indication, followed by rheumatological and gastrointestinal diseases.  Most patients experienced partial or complete resolution, or significant improvement.  23 adverse events were noted, including CD4 decreases, PJP (this person was not on ART at the time), sepsis (CD4 was 20), acute prostatitis, allergic reactions, tuberculosis reactivation, listeria meningitis, and CMV colitis.